As of 2025-04-29, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (81.72) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.48 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -1063.7%.
The range of the Relative Valuation is (80.82) - (109.90) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.1x - 25.0x | 16.8x |
| Forward P/E multiples | 15.1x - 21.9x | 15.8x |
| Fair Price | (80.82) - (109.90) | (81.72) |
| Upside | -1053.1% - -1396.0% | -1063.7% |
| Date | P/E |
| 2025-04-29 | -1.70 |
| 2025-04-28 | -1.69 |
| 2025-04-25 | -1.66 |
| 2025-04-24 | -1.63 |
| 2025-04-23 | -1.61 |
| 2025-04-22 | -1.66 |
| 2025-04-21 | -1.58 |
| 2025-04-17 | -1.44 |
| 2025-04-16 | -1.37 |
| 2025-04-15 | -1.47 |
| 2025-04-14 | -1.50 |
| 2025-04-11 | -1.48 |
| 2025-04-10 | -1.35 |
| 2025-04-09 | -1.41 |
| 2025-04-08 | -1.25 |
| 2025-04-07 | -1.30 |
| 2025-04-04 | -1.32 |
| 2025-04-03 | -1.37 |
| 2025-04-02 | -1.46 |
| 2025-04-01 | -1.33 |
| 2025-03-31 | -1.42 |
| 2025-03-28 | -1.61 |
| 2025-03-27 | -1.68 |
| 2025-03-26 | -1.66 |
| 2025-03-25 | -1.74 |
| 2025-03-24 | -1.86 |
| 2025-03-21 | -1.80 |
| 2025-03-20 | -1.74 |
| 2025-03-19 | -1.85 |
| 2025-03-18 | -1.83 |
| 2025-03-17 | -1.91 |
| 2025-03-14 | -1.82 |
| 2025-03-13 | -1.84 |
| 2025-03-12 | -1.92 |
| 2025-03-11 | -1.85 |
| 2025-03-10 | -1.89 |
| 2025-03-07 | -2.06 |
| 2025-03-06 | -1.97 |
| 2025-03-05 | -1.87 |
| 2025-03-04 | -1.81 |
| 2025-03-03 | -1.88 |
| 2025-02-28 | -2.01 |
| 2025-02-27 | -2.17 |
| 2025-02-26 | -2.15 |
| 2025-02-25 | -2.14 |
| 2025-02-24 | -2.30 |
| 2025-02-21 | -2.43 |
| 2025-02-20 | -2.44 |
| 2025-02-19 | -2.45 |
| 2025-02-18 | -2.30 |